<DOC>
	<DOCNO>NCT02225834</DOCNO>
	<brief_summary>Recent clinical trial meta-analyses b-hydroxy-bmethylglutaryl coenzyme A ( HMG-CoA ) reductase inhibitor ( statin ) demonstrate significant reduction ischemic stroke patient history coronary artery disease , without elevation serum cholesterol . Recent data suggest statins beneficial property addition retardation atherosclerosis . Asahi et al demonstred Statins increase eNOS tPA mRNA level change mRNA level PAI-1 In eNOS knockout mouse , atorvastatin reduced volume ischemic tissue improve neurologic outcome arterial occlusion blood clot embolus . In addition lipid-lowering effect , speculate statin may also beneficial effect cerebral circulation brain parenchyma ischaemic stroke reperfusion . Aslanyan et al report statin use associate reduced mortality 1 month follow-up . In patient recent stroke TIA without know coronary heart disease , 80 mg atorvastatin per day reduce overall incidence stroke cardiovascular event , despite small increase incidence hemorrhagic stroke period . Recently investigator group report lacunar stroke compare nonlacunar one exhibit significantly low plasma level TNF-α IL1-β , P-selectin ICAM-1 24-72 h 7-10 day stroke onset ( 4 ) . At extracranial arterial territory , inflammation play crucial role mediate stage atherosclerosis process . Similarly , thrombosis defective fibrinolysis may also contribute progression atherosclerotic lesion . Interestingly , mechanism might relevant role pathogenesis intracranial large artery atherosclerosis ischemic stroke Moreover group show Patients cardioembolic atherothrombotic stroke subtypes show significantly high median plasma level TNF-α , IL-6 , IL-1β whereas lacunar subtype show significantly low median plasma level TNF-α , IL-6 IL-1β immunoinflammatory marker plasma level significantly relate ischemic lesion volume . A meta-analysis show statin may possess antithrombotic property drug report reduce periprocedural infarction patient undergo percutaneous coronary intervention . This clinical benefit detect median , 0.5 day treatment statin ( indicate statin could potentially exert antithrombotic effect even earlier supposed pharmacological study . Violi et al recently show first evidence atorvastatin acutely simultaneously decrease oxidative stress platelet activation directly inhibit platelet Nox2 ultimately platelet isoprostanes thromboxane A2 providinf rationale use statins prevent modulate coronary thrombosis . Whereas recent data suggest inflammatory reaction involve pathogenesis progression cerebral ischaemia , study evaluate effect atorvastatin 80 mg/day recent stroke stroke outcome immunoinflammatory marker evaluate acute antithrombotic anti-inflammatory effect atorvastatin also acute cerebrovascular event set . On basis primary objective study evaluate separate effect atorvastatin vivo immunoinflammatory marker stroke prognosis patient recent acute ischemic stroke classify atherothrombotic .</brief_summary>
	<brief_title>Atorvastatin Acute Stroke Treatment</brief_title>
	<detailed_description>Material Methods The investigator enroll patient diagnosis acute ischemic stroke admit Internal Medicine Department University Palermo November 2011 October 2014 . The controlsubjects patient admit , period , Internal Medicine Department cause different acute cardiovascular cerebrovascular event exclusion criterion . Every subject ischemic stroke match age ( ±3 year ) , sex , cardiovascular risk factor prevalence one control subject Study Hypothesis Patient Population : The primary hypothesis study treatment 80 mg atorvastatin per day administer early admission acute ischemic stroke would reduce immunoinflammatory activation acute phase immunoinflammatory modulation could possible effect prognosis ischemic stroke evaluate outcome indicator . Eligible patient men woman 18 year age acute ischemic stroke Patients inflammatory infectious disease , cancer , hematological disease severe renal liver failure , well treatment anti-inflammatory exclude Stroke define focal neurological sign symptom think vascular origin persist &gt; 24 h , confirm brain CT and/or MRI baseline condition Cardiovascular risk factor evaluate subject controls basis follow criterion : type 2 diabetes determine use clinically base algorithm consider age onset , present weight symptom , family history , onset ofinsulin treatment , history ketoacidosis . Atrial fibrillation diagnose present admission ECG . Hypertension present patient receive antihypertensive treatment admission hypertension diagnose hospital stay repeat detection blood pressure ≥160/95 mmHg . Hypercholesterolemia define total serum cholesterol ≥200 mg/dl basis clinical history hypercholesterolemia statin treatment . The studyIs pending approvationby Ethics Committee `` Policlinico P. Giaccone '' Palermo . Written inform consent wasobtained patient . The type acute ischemic stroke classify accord TOAST classification ( Adams et al. , 1993 ) : 1 ) Large Artery Athero- Sclerosis ( LAAS ) ; 2 ) CardioEmbolic Infarct ( CEI ) ; 3 ) LACunar infarct ( LAC ) ; 4 ) stroke Other Determined Etiology ( ODE ) ; 5 ) stroke UnDetermined Etiology ( UDE ) . • Large artery atherosclerosis ( LAAS ) These patient clinical brain imaging finding either significant ( ≥50 % ) stenosis occlusion major brain artery branch cortical artery , presumably due atherosclerosis . Clinical finding include cerebral cortical impairment ( aphasia , neglect , restrict motor involvement , etc . ) brain stem cerebellar dysfunction . Cortical cerebellar lesion brain stem subcortical hemispheric infarct great 1.5 cm diameter CT MRI consider potential large artery atherosclerotic origin . Supportive evidence duplex image arteriography stenosis great 50 % appropriate intracranial extracranial artery need . Diagnostic study exclude potential source cardiogenic embolism . Patient evaluation blood sample collection All ischemic stroke patient undergo : medical history recordi ng potential stroke risk factor , blood coagulation test , 12-lead ECG , 24 h electrocardiography monitoring , trans-thoracic echocardiography , carotid ultrasound , brain CT MRI admission ( repeated third seventh day stroke onset ) . Blood sample obtain non-fasting state . After 10 min rest supine position , vital sign record blood sample collect antecubital vein . EDTA-anticoagulated peripheral blood drawn patient within 12 h symptom onset . Serum plasma immediately separate centrifugation store aliquot −80 °C analysis . The investigator evaluate plasma level IL-1β , TNF-α , IL-6 IL-10 , Eselectin , P-selectin , sICAM-1 sVCAM-1 marker immunoinflammatory activation , VWF plasma level marker endothelial dysfunction , TPA-antigen PAI-1 plasma level thrombotic/ fibrinolytic marker . These laboratory evaluation do 72 h one week symptom onset . IL-1β , TNF-α , IL-6 IL-10 VWFantigen measure use sandwich ELISA ( Human IL-1β , TNF-α , IL-6 IL-10 Quantikine , R &amp; D Systems ( VWF ELISA kitdurian , Instrumentation Laboratory , Milano , Italy ) ; VCAM-1 , ICAM-1 , E-selectin , P-selectin , PAI-1 TPAantigen measure commercial bioimmunoassay ( Human sICAM-1 , sVCAM-I , sE-selectin sP-selectin Parameter , Quantikine , R &amp; D Systems , Gentaur AssayMax Human Plasminogen Activator Inhibitor-1 ( PAI-1 ) ELISA Kit , Gentaur AssayMax Tissue Plasminogen Activator ( TPA ) ELISA Kit ) . The minimum detectable concentration diagnostic test : TNF alpha : 1.6 pg/mL , IL-1β : b1 pg/mL ; IL-6 : b0.70 pg/mL ; IL-10 : N3.9 pg/mL ; ICAM-1 : b0.35 ng/mL ; VCAM-1:0.6 ng/mL ; E-Selectin : b0.1 ng /mL ; P-Selectin : b0.5 ng/mL ; vWF:1.0 % ; TPA : 0.3 pg/ml ; PAI-1 : b50 pg/ml . Intra-assay inter-assay coefficient variation : TNF alpha : 4.2 % 4.6 % ; IL-1β : 3.3 % 4.2 % ; IL-6 : 1.6 % 3.3 % ; IL-10 : 4.3 % 7.5 % ; ICAM-1 : 4.8 % 6.1 % ; VCAM-1 : 3.5 % 7.7 % ; ESelectin : 4.8 % 5.7 % ; P-Selectin : 4.9 % 8.8 % ; vWF : 5 % 10 % ; TPA : 4.8 % 5 % ; PAI-1 : 5.7 % 8.3 % . As outcome indicator investigator use evaluation acute neurological deficit mean National Institutes Health Stroke Scale , 72 hour 7 day admission evaluation disability 7 day admission mean modify Rankin Scale Neurological deficit score admission evaluate NIHSS . The National Institutes Health Stroke Scale , NIH Stroke Scale ( NIHSS ) tool use healthcare provider objectively quantify impairment cause stroke . The NIHSS compose 11 item , score specific ability 0 4 . For item , score 0 typically indicate normal function specific ability , high score indicative level impairment . The individual score item sum order calculate patient 's total NIHSS score . The maximum possible score 42 , minimum score 0 Disability 7 day evaluate modified Rankin Scale ( mRS ) commonly use scale measure degree disability dependence daily activity people suffer stroke . The scale run 0-6 , run perfect health without symptom death . - 0 - No symptom . - 1 - No significant disability . Able carry usual activity , despite symptom . - 2 - Slight disability . Able look affair without assistance , unable carry previous activity . - 3 - Moderate disability . Requires help , able walk unassisted . - 4 - Moderately severe disability . Unable attend bodily need without assistance , unable walk unassisted . - 5 - Severe disability . Requires constant nursing care attention , bedridden , incontinent . - 6 - Dead . Treatment protocol Patients randomize two treatment : Group A : treatment atorvastatin 80 mg ( once-daily ) admission day discharge Group B : No treatment atorvastatin 80 mg discharge , discharge treatment atorvastatin 80 mg start</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Eligible patient men woman 18 year age acute ischemic stroke symptom time onset &lt; 48 hour Patients inflammatory infectious disease , cancer , hematological disease severe renal liver failure , well treatment antiinflammatory exclude</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Atorvastatin , ischemic stroke , cytokine</keyword>
</DOC>